Such an upregulation of tissue AP-A activity was not observed in the plasma implicating that IRAP inhibitor has the potential to normalize obesity-impaired release of AP-A into the circulation and normalize the levels of its soluble form. The gene discussed is ENPEP; the disease is obesity due to melanocortin 4 receptor deficiency.